Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT06376669
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Proton Stereotactic Body Radiation therapy (SBRT) — RADIATION
    Radiation therapy will consist of 3-5 treatments over 1.5 - 2 weeks

Study Details

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

Key Dates

Start date
Feb 25, 2025
Status verified
Apr 2026
Primary completion
Jun 30, 2027
Completion
Aug 31, 2030

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Proton Stereotactic Body Radiation Therapy (SBRT)
    The SBRT group is the single arm of this study.

Primary Outcome Measure

Change in kidney function after PROTON-BASED SBRT treatment as assessed by serum creatine levels [ Time Frame: Baseline and every 3-6 months up to 2 years post treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Sibley Memorial HospitalWashington D.C.District of Columbia20016
Sherif Shaaban
[email protected]
202-919-2523

Find similar trials in Washington D.C., DC

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Sibley Memorial Hospital· Washington D.C., DC

Related Studies